Insulizen

Insulin Resistance Reducer, Insulin Receptor Restore, And Blood Sugar Level Balance


Hcbiopharm Llc
Human Otc Drug
NDC 80353-451
Insulizen also known as Insulin Resistance Reducer, Insulin Receptor Restore, And Blood Sugar Level Balance is a human otc drug labeled by 'Hcbiopharm Llc'. National Drug Code (NDC) number for Insulizen is 80353-451. This drug is available in dosage form of Capsule. The names of the active, medicinal ingredients in Insulizen drug includes Lagerstroemia Speciosa Leaf - 1 [hp_X]/1 Morinda Citrifolia Fruit - 1 [hp_X]/1 . The currest status of Insulizen drug is Active.

Drug Information:

Drug NDC: 80353-451
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Insulizen
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Insulin Resistance Reducer, Insulin Receptor Restore, And Blood Sugar Level Balance
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Hcbiopharm Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Capsule
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:LAGERSTROEMIA SPECIOSA LEAF - 1 [hp_X]/1
MORINDA CITRIFOLIA FRUIT - 1 [hp_X]/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 24 Nov, 2021
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 07 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:HCBIOPHARM LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:OUK5B3W9E4
7829X3G2X5
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
80353-451-011 BOTTLE in 1 BOX (80353-451-01) / 1 CAPSULE in 1 BOTTLE (80353-451-02) / 60 CAPSULE in 1 CAPSULE (80353-451-03)24 Nov, 2021N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose reduces insulin resistance, restores defective insulin receptors, and maintains a normal blood sugar level*

Product Elements:

Insulizen insulin resistance reducer, insulin receptor restore, and blood sugar level balance lagerstroemia speciosa leaf lagerstroemia speciosa leaf morinda citrifolia fruit morinda citrifolia fruit curcuma longa whole eucommia ulmoides bark morus alba root bark momordica charantia fruit salvia miltiorrhiza root

Indications and Usage:

Use to reduce insulin resistance to restore defective insulin receptors to maintain a normal blood sugar level

Warnings:

Warning individuals with known medical conditions should consult a doctor prior to using this.

Dosage and Administration:

Directions take two (2) capsules daily 1 hour before breakfast.

Package Label Principal Display Panel:

Package label display insulizen insulin resistance reducer insulin receptor restore blood sugar level balance homeopathic 60 capsules insulizen


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.